Articles written by: Dolores Ford

CytomX Therapeutics, Inc. (CTMX) Analysts See $-0.49 EPS

CytomX Therapeutics, Inc. (CTMX) Analysts See $-0.49 EPS

Analysts expect CytomX Therapeutics, Inc. (NASDAQ:CTMX) to report $-0.49 EPS on March, 6.They anticipate $0.51 EPS change or 2,550.00 % from last quarter’s $0.02 EPS. After having $-0.53 EPS previously, CytomX Therapeutics, Inc.’s analysts see -7.55 % EPS growth. The stock decreased 1.41% or $0.26 during the last trading session, […]

$0.12 EPS Expected for CryoLife, Inc. (CRY)

$0.12 EPS Expected for CryoLife, Inc. (CRY)

Investors sentiment decreased to 1.11 in Q3 2018. Its down 0.56, from 1.67 in 2018Q2. It turned negative, as 5 investors sold CryoLife, Inc. shares while 41 reduced holdings. 22 funds opened positions while 29 raised stakes. 25.56 million shares or 3.16% more from 24.77 million shares in 2018Q2 were […]

17.20 % to Target, RBC Capital Reconfirms ‘”Buy”’ Rating on Huntsman Corp (NYSE:HUN) Shares Today

17.20 % to Target, RBC Capital Reconfirms ‘”Buy”’ Rating on Huntsman Corp (NYSE:HUN) Shares Today

Investors sentiment increased to 1.46 in Q3 2018. Its up 0.33, from 1.13 in 2018Q2. It improved, as 34 investors sold Huntsman Corporation shares while 94 reduced holdings. 51 funds opened positions while 136 raised stakes. 175.95 million shares or 0.20% less from 176.31 million shares in 2018Q2 were reported. […]

EPS for THL Credit, Inc. (TCRD) Expected At $0.27

EPS for THL Credit, Inc. (TCRD) Expected At $0.27

Investors sentiment increased to 0.9 in Q3 2018. Its up 0.20, from 0.7 in 2018Q2. It improved, as 15 investors sold THL Credit, Inc. shares while 14 reduced holdings. 13 funds opened positions while 13 raised stakes. 10.65 million shares or 2.18% more from 10.43 million shares in 2018Q2 were […]

Timbercreek Financial Corporation (TF) Analysts See $0.18 EPS

Analysts expect Timbercreek Financial Corporation (TSE:TF) to report $0.18 EPS on March, 5.They anticipate $0.01 EPS change or 5.88 % from last quarter’s $0.17 EPS. T_TF’s profit would be $14.69M giving it 12.90 P/E if the $0.18 EPS is correct. After having $0.17 EPS previously, Timbercreek Financial Corporation’s analysts see […]

$-0.30 EPS Expected for GlycoMimetics, Inc. (GLYC)

$-0.30 EPS Expected for GlycoMimetics, Inc. (GLYC)

Investors sentiment decreased to 1.26 in Q3 2018. Its down 0.11, from 1.37 in 2018Q2. It worsened, as 9 investors sold GlycoMimetics, Inc. shares while 22 reduced holdings. 13 funds opened positions while 26 raised stakes. 45.77 million shares or 0.31% less from 45.91 million shares in 2018Q2 were reported. […]

Cryoport, Inc. (CYRX) EPS Estimated At $-0.07

Analysts expect Cryoport, Inc. (NASDAQ:CYRX) to report $-0.07 EPS on March, 5.They anticipate $0.02 EPS change or 22.22 % from last quarter’s $-0.09 EPS. After having $-0.07 EPS previously, Cryoport, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 2.93% or $0.35 during the last trading session, reaching $11.6. […]

BidaskScore Decides to Upgrade Huami Corporation (NYSE:HMI). Will Other Analysts Follow Suit?

Huami Corporation (NYSE:HMI) Stock Upgrade New York-listed Huami Corporation (NYSE:HMI), was boosted by equity analysts at BidaskScore, who boosted its rating on the $976.80 million market cap company to a solid “Buy”. The stock increased 10.25% or $1.51 during the last trading session, reaching $16.24. About 925,059 shares traded or […]

Analysts at Merrill Lynch Kept the Same their Past ‘”Buy”’ rating on Shares Agnico Eagle (NYSE:AEM), Set a $52.5 Price Objective

Analysts at Merrill Lynch Kept the Same their Past ‘”Buy”’ rating on Shares Agnico Eagle (NYSE:AEM), Set a $52.5 Price Objective

Agnico Eagle (NYSE:AEM) Rating Reaffirmed In a research note revealed to investors on 19 February, The “Buy” rating of Agnico Eagle (NYSE:AEM) shares was reconfirmed by Analysts at Merrill Lynch, who now has a $52.5 PT on the stock. Merrill Lynch’s PT indicates a possible upside of 21.25 % from […]

Syndax Pharmaceuticals, Inc. (SNDX) EPS Estimated At $-0.66

Syndax Pharmaceuticals, Inc. (SNDX) EPS Estimated At $-0.66

Analysts expect Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to report $-0.66 EPS on March, 4.They anticipate $0.14 EPS change or 17.50 % from last quarter’s $-0.8 EPS. After having $-0.68 EPS previously, Syndax Pharmaceuticals, Inc.’s analysts see -2.94 % EPS growth. The stock decreased 1.41% or $0.09 during the last trading session, […]